ReviewMedical oncology (Northwood, London, England)2017
Oncolytic viruses: emerging options for the treatment of breast cancer.
Review in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The Impact of Microbiome on Breast Cancer and Regulatory Strategies.Microorganisms · 2025Review
- Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry.Frontiers in immunology · 2024Review
- New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.Frontiers in immunology · 2024Review
- Breast cancer immunotherapy: a comprehensive review.Clinical and experimental medicine · 2023Review
- Review
- MicroRNA-detargeting proves more effective thanMolecular therapy oncolytics · 2021Article
- Review
- Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology.Medicina (Kaunas, Lithuania) · 2019Review
- Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy.Cancers · 2019Article
- Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells.Scientific reports · 2019Article
- Perspectives on immunotherapy via oncolytic viruses.Infectious agents and cancer · 2019Review
- Progress in gene therapy using oncolytic vaccinia virus as vectors.Journal of cancer research and clinical oncology · 2018Review
- T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.Medical oncology (Northwood, London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common type of cancer among women and is the second most common cause of cancer-related deaths, following lung cancer. Severe toxicity associated with a long-term use of BC chemo- and radiotherapy makes it essential to look for newer therapeutics. Additionally, molecular heterogeneity at both intratumoral and intertumoral levels among BC subtypes is known to result in a differential response to standard therapeutics. Oncolytic viruses (OVs) have emerged as one of the most promising treatment options for BC. Many preclinical and clinical studies have shown that OVs are effective in treating BC, both as a single therapeutic agent and as a part of combination therapies. Combination therapies involving multimodal therapeutics including OVs are becoming popular as they allow to achieve the synergistic therapeutic effects, while minimizing the associated toxicities. Here, we review the OVs for BC therapy in preclinical studies and in clinical trials, both as a monotherapy and as part of a combination therapy. We also briefly discuss the potential therapeutic targets for BC, as these are likely to be critical for the development of new OVs.
Indexed as
Identifiers
28185165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.